The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental therapy called cintredekin besudotox (IL13-PE38QQR), which Precision Neuromed is…
News
GYNECOLOGICAL CANCER
Prolactin-raising antipsychotics may increase gynecological cancer risk
Women prescribed antipsychotics that raise the levels of prolactin, a hormone that stimulates milk production and regulates reproductive hormones, had double the rate of…
C4 Therapeutics and Pfizer are teaming up to evaluate whether combining C4’s investigational oral therapy cemsidomide with Pfizer’s approved multiple myeloma treatment Elrexfio…
The U.S. Food and Drug Administration has approved a new rapid diagnostic test to identify patients with treatment-resistant acute leukemias who may benefit from the…
PANCREATIC CANCER
Utidelone now FDA orphan drug after promising cancer trial results
Biostar Pharma’s experimental therapy utidelone has been granted orphan drug status for pancreatic cancer by the U.S. Food and Drug Administration (FDA). The…
The experimental therapy iopofosine I 131Â may improve survival outcomes in children and young adults with hard-to-treat glioma, according to new clinical trial data announced…
GYNECOLOGICAL CANCER
Stenoparib may improve survival in hard-to-treat ovarian cancer: Data
The experimental therapy stenoparib (2X-121) may help extend survival in people with hard-to-treat ovarian cancer, according to new clinical trial data announced by the therapy’s…
PANCREATIC CANCER
Atebimetinib yields ‘extraordinary’ results in pancreatic cancer trial
An experimental cancer therapy known as atebimetinib is delivering “extraordinary” results for patients with pancreatic cancer. New data from an ongoing Phase 2a clinical…
The European Commission has approved Voranigo (vorasidenib) for certain types of glioma, marking the arrival of a new targeted pill poised to change…
GYNECOLOGICAL CANCER
FDA decision on relacorilant for ovarian cancer expected in July
The U.S. Food and Drug Administration (FDA) has agreed to review Corcept Therapeutics’ application seeking approval of relacorilant to treat platinum-resistant ovarian cancer. The…
Recent Posts
- Overt forms advisory board to guide ovarian cancer therapy push
- CAR T-cell therapy moving to frontline as myeloma treatment
- The spotlight on multiple myeloma will have many seeing red this week
- New registry aims to support research for pediatric acute myeloid leukemia
- New AI-based tool aims to help guide treatment for pancreatic cancer
